# A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

> **NCT07391657** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 508 (estimated)

## Conditions studied

- Relapsed Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** AZD0120
- **DRUG:** Daratumumab
- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone
- **DRUG:** Bortezomib
- **DRUG:** Pomalidomide

## Key facts

- **NCT ID:** NCT07391657
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-23
- **Primary completion:** 2028-06-14
- **Final completion:** 2030-08-12
- **Target enrollment:** 508 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07391657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07391657, "A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT07391657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*